Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Alzheimer's Research & Therapy
Published in: Alzheimer's Research & Therapy 1/2024

Open Access 01-12-2024 | Alzheimer's Disease | Research

Alteration of medial temporal lobe metabolism related to Alzheimer’s disease and dementia with lewy bodies

Authors: Sungwoo Kang, Seun Jeon, Young-gun Lee, Byoung Seok Ye

Published in: Alzheimer's Research & Therapy | Issue 1/2024

Login to get access

Abstract

Background

Association of medial temporal lobe (MTL) metabolism with Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) has not been evaluated considering their mixed disease (MD).

Methods

131 patients with AD, 133 with DLB, 122 with MD, and 28 normal controls (NCs) underwent neuropsychological tests, assessments for parkinsonism, cognitive fluctuation (CF), and visual hallucinations (VH), and 18F-fluorodeoxyglucose PET to quantify MTL metabolism in the amygdala, hippocampus, and entorhinal cortex. The effects of AD and DLB on MTL metabolism were evaluated using general linear models (GLMs). Associations between MTL metabolism, cognition, and clinical features were evaluated using GLMs or logistic regression models separately performed for the AD spectrum (NC + AD + MD), DLB spectrum (NC + DLB + MD), and disease groups (AD + DLB + MD). Covariates included age, sex, and education.

Results

AD was associated with hippocampal/entorhinal hypometabolism, whereas DLB was associated with relative amygdalar/hippocampal hypermetabolism. Relative MTL hypermetabolism was associated with lower attention/visuospatial/executive scores and severe parkinsonism in both the AD and DLB spectra and disease groups. Left hippocampal/entorhinal hypometabolism was associated with lower verbal memory scores, whereas right hippocampal hypometabolism was associated with lower visual memory scores in both the AD spectrum and disease groups. Relative MTL hypermetabolism was associated with an increased risk of CF and VH in the disease group, and relative amygdalar hypermetabolism was associated with an increased risk of VH in the DLB spectrum.

Conclusions

Entorhinal-hippocampal hypometabolism and relative amygdala-hippocampal hypermetabolism could be characteristics of AD- and DLB-related neurodegeneration, respectively.
Appendix
Available only for authorised users
Literature
1.
Hamilton RL. Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000;10(3):378–84.PubMedCrossRef
2.
Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 2017;16(1):55–65.PubMedPubMedCentralCrossRef
3.
McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100.PubMedPubMedCentralCrossRef
4.
Coughlin DG, Hurtig HI, Irwin DJ. Pathological influences on clinical heterogeneity in Lewy Body Diseases. Mov Disord. 2020;35(1):5–19.PubMedCrossRef
5.
Chung EJ, Babulal GM, Monsell SE, Cairns NJ, Roe CM, Morris JC. Clinical features of Alzheimer Disease with and without Lewy Bodies. JAMA Neurol. 2015;72(7):789–96.PubMedPubMedCentralCrossRef
6.
Braak H, Braak E. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16(3):271–8. discussion 8–84.PubMedCrossRef
7.
Rezaie P, Cairns NJ, Chadwick A, Lantos PL. Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease. Neurosci Lett. 1996;212(2):111–4.PubMedCrossRef
8.
Nelson PT, Abner EL, Patel E, Anderson S, Wilcock DM, Kryscio RJ, et al. The Amygdala as a locus of pathologic misfolding in neurodegenerative diseases. J Neuropathol Exp Neurol. 2018;77(1):2–20.PubMedCrossRef
9.
Nestor PJ, Altomare D, Festari C, Drzezga A, Rivolta J, Walker Z, et al. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. Eur J Nucl Med Mol Imaging. 2018;45(9):1509–25.PubMedCrossRef
10.
11.
Pillai JA, Wu G, Tousi B, Larvie M, Léger GC, Leverenz JB. Amygdala sign, a FDG-PET signature of dementia with Lewy Bodies. Parkinsonism Relat Disord. 2019;64:300–3.PubMedPubMedCentralCrossRef
12.
Kantarci K, Boeve BF, Przybelski SA, Lesnick TG, Chen Q, Fields J, et al. FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage. Clinical. 2021;31:102754.
13.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.PubMedCrossRef
14.
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9.PubMedCrossRef
15.
McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743–55.PubMedPubMedCentralCrossRef
16.
Lee YG, Jeon S, Kang SW, Ye BS. Effects of amyloid beta and dopaminergic depletion on perfusion and clinical symptoms. Alzheimers Dement. 2023;19(12):5719–29.PubMedCrossRef
17.
Kang Y, Na D. Seoul Neuropsychological Screening Battery (SNSB): Human Brain Research & Consulting Co. In: Incheon; 2003.
18.
Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging. 2001;20(1):45–57.PubMedCrossRef
19.
Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A bayesian model of shape and appearance for subcortical brain segmentation. NeuroImage. 2011;56(3):907–22.PubMedCrossRef
20.
Rolls ET, Huang CC, Lin CP, Feng J, Joliot M. Automated anatomical labelling atlas 3. NeuroImage. 2020;206:116189.PubMedCrossRef
21.
Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC. A reproducible evaluation of ANTs similarity metric performance in brain image registration. NeuroImage. 2011;54(3):2033–44.PubMedCrossRef
22.
Moeller JR, Strother SC. A Regional Covariance Approach to the analysis of functional patterns in Positron Emission Tomographic Data. J Cereb Blood Flow Metabolism. 1991;11(1suppl):A121–35.CrossRef
23.
Lee YG, Jeon S, Yoo HS, Chung SJ, Lee SK, Lee PH, et al. Amyloid-beta-related and unrelated cortical thinning in dementia with Lewy bodies. Neurobiol Aging. 2018;72:32–9.PubMedCrossRef
24.
Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study. Alzheimers Dement. 2015;11(8):964–74.PubMedCrossRef
25.
Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer’s disease and mild cognitive impairment. Ann Neurol. 2003;54(3):343–51.PubMedCrossRef
26.
Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, Convit A, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology. 2005;64(11):1860–7.PubMedCrossRef
27.
Karow DS, McEvoy LK, Fennema-Notestine C, Hagler DJ Jr., Jennings RG, Brewer JB, et al. Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. Radiology. 2010;256(3):932–42.PubMedPubMedCentralCrossRef
28.
Walhovd KB, Fjell AM, Brewer J, McEvoy LK, Fennema-Notestine C, Hagler DJ Jr., et al. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol. 2010;31(2):347–54.PubMedPubMedCentralCrossRef
29.
Ye BS, Lee S, Yoo H, Chung SJ, Lee YH, Choi Y, et al. Distinguishing between dementia with Lewy bodies and Alzheimer’s disease using metabolic patterns. Neurobiol Aging. 2020;87:11–7.PubMedCrossRef
30.
Huang C, Ravdin LD, Nirenberg MJ, Piboolnurak P, Severt L, Maniscalco JS, et al. Neuroimaging markers of motor and nonmotor features of Parkinson’s disease: an 18f fluorodeoxyglucose positron emission computed tomography study. Dement Geriatr Cogn Disord. 2013;35(3–4):183–96.PubMedCrossRef
31.
Diaz-Galvan P, Miyagawa T, Przybelski SA, Lesnick TG, Senjem ML, Jack CR, et al. Brain glucose metabolism and nigrostriatal degeneration in isolated rapid eye movement sleep behaviour disorder. Brain Commun. 2023;5(1):fcad021.PubMedPubMedCentralCrossRef
32.
Ishii K, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, Mori E. Relatively preserved hippocampal glucose metabolism in mild Alzheimer’s disease. Dement Geriatr Cogn Disord. 1998;9(6):317–22.PubMedCrossRef
33.
Ishii K, Sasaki H, Kono AK, Miyamoto N, Fukuda T, Mori E. Comparison of gray matter and metabolic reduction in mild Alzheimer’s disease using FDG-PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging. 2005;32(8):959–63.PubMedCrossRef
34.
Milner B. BMemory and the medial temporal regions of the brain,[in Biology of memory, KH Pribram and DE Broadbent. Eds. New York: Academic; 1970. pp. 29–50.
35.
Bonelli SB, Powell RHW, Yogarajah M, Samson RS, Symms MR, Thompson PJ, et al. Imaging memory in temporal lobe epilepsy: predicting the effects of temporal lobe resection. Brain. 2010;133(4):1186–99.PubMedPubMedCentralCrossRef
36.
Nagy Z, Jobst KA, Esiri MM, Morris JH, King EM, MacDonald B, et al. Hippocampal pathology reflects memory deficit and brain imaging measurements in Alzheimer’s disease: clinicopathologic correlations using three sets of pathologic diagnostic criteria. Dementia. 1996;7(2):76–81.PubMed
37.
Reitz C, Honig L, Vonsattel JP, Tang MX, Mayeux R. Memory performance is related to amyloid and tau pathology in the hippocampus. J Neurol Neurosurg Psychiatry. 2009;80(7):715–21.PubMedCrossRef
38.
Kang S, Yoon SH, Na HK, Lee Y-g, Jeon S, Baik K et al. Neuropsychological comparison of patients with Alzheimer’s Disease and Dementia with Lewy Bodies. J Clin Neurol. 2023;19.
39.
Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, Bennett DA. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain. 2012;135(Pt 10):3005–14.PubMedPubMedCentralCrossRef
40.
El-Nazer R, Adler CH, Beach TG, Belden CM, Artz J, Shill HA, et al. Regional neuropathology distribution and verbal fluency impairments in Parkinson’s disease. Parkinsonism Relat Disord. 2019;65:73–8.PubMedPubMedCentralCrossRef
41.
Huber M, Beyer L, Prix C, Schönecker S, Palleis C, Rauchmann BS, et al. Metabolic correlates of dopaminergic loss in dementia with Lewy Bodies. Mov Disord. 2020;35(4):595–605.PubMedCrossRef
42.
Kang SW, Jeon S, Lee Y-g, Park M, Baik K, Jung JH, et al. Implication of metabolic and dopamine transporter PET in dementia with Lewy bodies. Sci Rep. 2021;11(1):14394.PubMedPubMedCentralCrossRef
43.
Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer’s disease: an independent component analysis. J Neurosci. 2006;26(40):10222–31.PubMedPubMedCentralCrossRef
44.
Li S, Varga V, Sik A, Kocsis B. GABAergic control of the ascending input from the median raphe nucleus to the limbic system. J Neurophysiol. 2005;94(4):2561–74.PubMedCrossRef
45.
Plenz D, Kital ST. A basal ganglia pacemaker formed by the subthalamic nucleus and external Globus Pallidus. Nature. 1999;400(6745):677–82.PubMedCrossRef
46.
Mouginot D, Gähwiler BH. Characterization of synaptic connections between cortex and deep nuclei of the rat cerebellum in vitro. Neuroscience. 1995;64(3):699–712.PubMedCrossRef
47.
Blatt GJ, Oblak AL, Schmahmann JD. Cerebellar connections with limbic circuits: anatomy and functional implications. In: Manto M, Schmahmann JD, Rossi F, Gruol DL, Koibuchi N, editors. Handbook of the Cerebellum and Cerebellar disorders. Dordrecht: Springer Netherlands; 2013. pp. 479–96.CrossRef
48.
Morris M, Sanchez PE, Verret L, Beagle AJ, Guo W, Dubal D, et al. Network dysfunction in alpha-synuclein transgenic mice and human Lewy body dementia. Ann Clin Transl Neurol. 2015;2(11):1012–28.PubMedPubMedCentralCrossRef
49.
Harding AJ, Stimson E, Henderson JM, Halliday GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson’s disease. Brain. 2002;125(Pt 11):2431–45.PubMedCrossRef
50.
Shaw CM, Alvord EC. Jr. Neuropathology of the limbic system. Neuroimaging Clin N Am. 1997;7(1):101–42.PubMed
51.
Lee Y-g, Jeon S, Park M, Kang SW, Yoon SH, Baik K, et al. Effects of Alzheimer and Lewy Body Disease pathologies on Brain Metabolism. Ann Neurol. 2022;91(6):853–63.PubMedCrossRef
Metadata
Title
Alteration of medial temporal lobe metabolism related to Alzheimer’s disease and dementia with lewy bodies
Authors
Sungwoo Kang
Seun Jeon
Young-gun Lee
Byoung Seok Ye
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Alzheimer's Research & Therapy / Issue 1/2024
Electronic ISSN: 1758-9193
DOI
https://doi.org/10.1186/s13195-024-01429-4

Other articles of this Issue 1/2024

Alzheimer's Research & Therapy 1/2024 Go to the issue

Research

A nonhuman primate model with Alzheimer’s disease-like pathology induced by hippocampal overexpression of human tau

Research

Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy

Research

Subclinical epileptiform activity in the Alzheimer continuum: association with disease, cognition and detection method

Research

Unveiling the sound of the cognitive status: Machine Learning-based speech analysis in the Alzheimer’s disease spectrum

Research

Amyloid β oligomer induces cerebral vasculopathy via pericyte-mediated endothelial dysfunction

Research

Relationships of change in Clinical Dementia Rating (CDR) on patient outcomes and probability of progression: observational analysis